Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891023 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL12349380 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL11995104 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL18073498 | 0.78 | GRIA1 (0.43) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL13843643 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL12393019 | 0.77 | BRD4 (0.37) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL13843642 | 0.75 | KDM4E (0.33) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL24714559 | 0.74 | HTR7 (0.41) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL17169606 | 0.74 | HTR7 (0.41) | KDM4EALDH1A1GAAHPGDALOX12 | |
| SCHEMBL13847595 | 0.74 | KDM4E (0.44) | KDM4EALDH1A1GAAHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309428-A1 | USE OF TRANSITION METAL CARBENE COMPLEXES IN ORGANIC LIGHT-EMITTING DIODES (OLEDS) | BASF SE (DE) | 2014-10-16 | — | — | US | disclosed |
| US-8384068-B2 | Use of acridine derivatives as matrix materials and/or electron blockers in OLEDs | BASF SE (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8373159-B2 | Organic light-emitting diodes comprising carbene-transition metal complex emitter, and at least one compound selected from disilylcarbazoles, disilyldibenzofurans, disilyldibenzothiophenes, disilyldibenzophospholes, disilyldibenzothiophene s-oxides and disilyldibe | BASF SE (DE) | 2013-02-12 | — | — | US | disclosed |
| US-7989091-B2 | Silanes containing phenothiazine-S-oxide or phenothiazine-S,S-dioxide groups and the use thereof in OLEDs | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100219406-A1 | USE OF ACRIDINE DERIVATIVES AS MATRIX MATERIALS AND/OR ELECTRON BLOCKERS IN OLEDS | BASF SE (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100219403-A1 | ORGANIC LIGHT-EMITTING DIODES COMPRISING CARBENE-TRANSITION METAL COMPLEX EMITTERS, AND AT LEAST ONE COMPOUND SELECTED FROM DISILYLCARBAZOLES, DISILYLDIBENZOFURANS, DISILYLDIBENZOTHIOPHENES, DISILYLDIBENZOPHOSPHOLES, DISILYLDIBENZOTHIOPHENE S-OXIDES AND DISILYLDIBENZOTHIOPHENE S,S-DIOXIDES | BASF SE (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100187980-A1 | SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20080018238-A1 | Use Of Phenothiazine-S-Oxides And Phenothiazine -S,S-Dioxides In The Form Of Matrix Materials For Organic Light-Emitting Diodes | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080018221-A1 | Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100187980-A1 | SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS | OPRD1, PPID, PLOD2 | KDM4E 2722/4885ALDH1A1 980/4885GAA 3574/4885 |
| US-20080018221-A1 | Use Of Transition Metal Carbene Complexes In Organic Light-Emitting Diodes (Oleds) | OCIAD2, OCIAD1, ICOSLG | KDM4E 4325/4885ALDH1A1 1981/4885GAA 3714/4885 |
| US-20100219403-A1 | ORGANIC LIGHT-EMITTING DIODES COMPRISING CARBENE-TRANSITION METAL COMPLEX EMITTERS, AND AT LEAST ONE COMPOUND SELECTED FROM DISILYLCARBAZOLES, DISILYLDIBENZOFURANS, DISILYLDIBENZOTHIOPHENES, DISILYLDIBENZOPHOSPHOLES, DISILYLDIBENZOTHIOPHENE S-OXIDES AND DISILYLDIBENZOTHIOPHENE S,S-DIOXIDES | DDT, GRIN2B, DRD1 | KDM4E 3445/4885ALDH1A1 1149/4885GAA 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.